Cargando…

A Versatile Microencapsulation Platform for Hyaluronic Acid and Polyethylene Glycol

Cell microencapsulation is a rapidly expanding field with broad potential for stem cell therapies and tissue engineering research. Traditional alginate microspheres suffer from poor biocompatibility, and microencapsulation of more advanced hydrogels is challenging due to their slower gelation rates....

Descripción completa

Detalles Bibliográficos
Autores principales: Harrington, Stephen, Ott, Lindsey, Karanu, Francis, Ramachandran, Karthik, Stehno-Bittel, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891217/
https://www.ncbi.nlm.nih.gov/pubmed/32103710
http://dx.doi.org/10.1089/ten.tea.2019.0286
Descripción
Sumario:Cell microencapsulation is a rapidly expanding field with broad potential for stem cell therapies and tissue engineering research. Traditional alginate microspheres suffer from poor biocompatibility, and microencapsulation of more advanced hydrogels is challenging due to their slower gelation rates. We have developed a novel, noncytotoxic, nonemulsion-based method to produce hydrogel microspheres compatible with a wide variety of materials, called core-shell spherification (CSS). Fabrication of microspheres by CSS derived from two slow-hardening hydrogels, hyaluronic acid (HA) and polyethylene glycol diacrylate (PEGDA), was characterized. HA microspheres were manufactured with two different crosslinking methods: thiolation and methacrylation. Microspheres of methacrylated HA (MeHA) had the greatest swelling ratio, the largest average diameter, and the lowest diffusion barrier. In contrast, PEGDA microspheres had the smallest diameters, the lowest swelling ratio, and the highest diffusion barrier, while microspheres of thiolated HA had characteristics that were in between the other two groups. To test the ability of the hydrogels to protect cells, while promoting function, diabetic NOD mice received intraperitoneal injections of PEGDA or MeHA microencapsulated canine islets. PEGDA microspheres reversed diabetes for the length of the study (up to 16 weeks). In contrast, islets encapsulated in MeHA microspheres at the same dose restored normoglycemia, but only transiently (3–4 weeks). Nonencapsulated canine islet transplanted at the same dose did not restore normoglycemia for any length of time. In conclusion, CSS provides a nontoxic microencapsulation procedure compatible with various hydrogel types. IMPACT STATEMENT: Core-shell spherification, described here for the first time, is a versatile method of coating cells to protect them following transplantation. Before the invention of this technique, only instantaneously hardening hydrogels, like alginate, could be used to encapsulate cells. With this new technology, biocompatible hydrogels can now be used for encapsulation without harsh emulsion chemicals. The technique involves a temporary shell of alginate around the slow-hardening gel that provides time for crosslinking to occur. Subsequently, the alginate shell is easily removed, leaving the cells in a protective microsphere with a higher surface area for diffusion than large encapsulating devices.